经FDA批准并由医生监督

GLP-1 医疗减重计划

多年来一直在为减肥而苦恼吗?
获得医生处方的解决方案,通过调节食欲并解决荷尔蒙和代谢因素,支持可持续减重。

-12.4%

Average weight change, top dose (1)

72 Weeks

ATTAIN-1 trial duration (1)

Any time

With or without food or water (3)

💡

A note on terminology

This page uses orforglipron, the generic name, rather than any brand name, in line with Singapore's medical advertising guidelines, which restrict reference to registered trade names.

Where orforglipron stands today

Orforglipron is new, so it helps to know exactly what has and hasn't been approved before you speak to a doctor.

✓ 2023 — Phase 2 results published. Early trials showed weight loss that increased with the dose over 36 weeks, which led to large phase 3 studies. (4)

✓ 2025 — Phase 3 ATTAIN trials reported. Two 72-week trials tested orforglipron in adults with obesity or overweight, one without diabetes and one with type 2 diabetes. (1) (2)

✓ April 2026 — Approved overseas for weight management. US regulators approved orforglipron for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Approvals in the United Kingdom, the United Arab Emirates, Saudi Arabia and China followed later in 2026. (3)

▸ Singapore — Not yet registered. At the time of writing (November 2026), orforglipron is not registered with HSA, so doctors here cannot prescribe it. Please avoid overseas or online sellers: unregistered weight loss products may be fake or unsafe. (5) (6)

How does a GLP-1 pill work?

GLP-1 is a hormone the gut releases after you eat. It tells the brain you are full, slows how quickly the stomach empties, and helps the pancreas release insulin when blood sugar rises.

Most GLP-1 medicines are peptides, small proteins that stomach acid breaks down. That is why they are usually injected, and why the one existing GLP-1 tablet needs a strict empty-stomach routine to be absorbed.

Orforglipron is a small, non-peptide molecule that still switches on the GLP-1 receptor. It survives digestion, so it can be swallowed as an ordinary tablet once a day, at any time, with or without food. (3) (4)

Fig. 1 — Why orforglipron can be taken as a tablet: peptide versus small-molecule GLP-1.
Fig. 1 — Why orforglipron can be taken as a tablet: peptide versus small-molecule GLP-1.
Fig. 2 — From a daily tablet to gradual weight loss.
Fig. 2 — From a daily tablet to gradual weight loss.

What the ATTAIN trials found

ATTAIN-1 and ATTAIN-2 were phase 3, randomised, double-blind, placebo-controlled trials run over 72 weeks. Everyone taking part also received advice on diet and physical activity. (1) (2)

Trial

Population (n)

Weight change, top dose

Weight change, placebo

Type 2 diabetes

ATTAIN-1

3,127 · obesity or overweight

-12.4%

-0.9%

No

ATTAIN-2

1,613 · obesity or overweight

-10.5%

-2.2%

Yes

ATTAIN-1: adults without diabetes

At 72 weeks, people on the highest dose (36 mg) lost an average of 12.4% of their body weight, compared with 0.9% on placebo. Weight came off gradually and was still falling slowly towards the end of the trial. (1)

ATTAIN-2: adults with type 2 diabetes

People with type 2 diabetes usually lose less weight on GLP-1 medicines than people without it. On the highest dose, average weight loss was 10.5% versus 2.2% on placebo, alongside lower blood sugar (HbA1c). (2)

Fig. 3 — Average change in body weight at week 72 in ATTAIN-1 and ATTAIN-2, highest dose versus placebo.
Fig. 3 — Average change in body weight at week 72, highest dose versus placebo. Source: ATTAIN-1 and ATTAIN-2 (1)(2).
What else did the trials measure?

Besides body weight, the ATTAIN trials tracked several heart and metabolic markers. Orforglipron was associated with improvements in:

  • Waist circumference
  • Systolic blood pressure
  • Triglycerides
  • Non-HDL cholesterol
  • hs-CRP, a marker of inflammation
  • HbA1c, in people with type 2 diabetes

These were secondary measures. The trials were not designed to show whether orforglipron prevents heart attacks or strokes; longer studies looking at those outcomes are still running. (1) (2)

Because orforglipron has no fasting window, it can be taken alongside other morning medicines. A simpler routine can make it easier to stay on treatment, which matters, because weight loss medicines only work for as long as they are taken.

Why keeping weight off matters

When GLP-1 treatment stops, appetite usually returns and weight tends to come back. Researchers are now studying whether a daily tablet like orforglipron could help people hold on to their weight loss after a course of weekly injections. (7)

How does it compare with weekly injections?

Orforglipron joins a group of GLP-1 medicines that already includes weekly semaglutide and tirzepatide injections. Here is how they compare on the evidence so far.

In their own phase 3 trials, weekly semaglutide 2.4 mg produced average weight loss of about 15% over 68 weeks, and weekly tirzepatide about 21% at its highest dose over 72 weeks. (8) (9)

Orforglipron's average result, about 11 to 12%, is lower. The trials enrolled different people and were not run head to head, though, so the numbers can't be compared directly.

The trade-off is convenience: one tablet a day, no needles and no timing rules. For some people, that makes long-term treatment easier to keep up. A doctor can help you weigh these factors against your health goals.

Fig. 4 — Orforglipron versus weekly GLP-1 injections at a glance.
Fig. 4 — Orforglipron versus weekly GLP-1 injections at a glance.

Side effects and tolerability

在整个治疗过程中,医疗监督是必要的,以确保患者的安全和治疗的有效性。

Commonly reported effects

  • Nausea
  • Constipation
  • Diarrhoea
  • Vomiting
  • Indigestion
  • Reduced appetite
预约咨询并检查您的资格
减肥有时会让人感到不知所措和充满挑战。然而,您不必独自面对。有了正确的治疗方案和专业的指导,您可以实现可持续的减肥,并自信地重获健康。

立即预约咨询,获取全面的身体分析和个性化治疗方案。
预约咨询
常见问题
参考文献

Studies and sources cited in this document

  1. Wharton S, et al., for the ATTAIN-1 Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, for Obesity. N Engl J Med. 2025.
  2. Eli Lilly and Company. ATTAIN-2: orforglipron in adults with obesity or overweight and type 2 diabetes. Topline phase 3 results, 2025.
  3. U.S. Food and Drug Administration. Approval of orforglipron for chronic weight management in adults. April 1, 2026.
  4. Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389:877-888.
  5. Health Sciences Authority, Singapore. Register of Therapeutic Products. Checked November 2026.
  6. Health Sciences Authority, Singapore. Public advisories on illegal and unregistered weight loss products.
  7. Eli Lilly and Company. ATTAIN-MAINTAIN: a phase 3 study of orforglipron to maintain weight loss after injectable GLP-1 treatment.
  8. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
  9. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.

Detect any underlying health conditions.

您上次进行全面体检是什么时候?掌控您的健康——从一次 全面全身健康检查 并咨询您的医生。

请说明您目前的问题,或分享任何其他需要在您预约前告知我们的备注。

今天就开始掌控您的健康。

您的提交已收到。
您的提交已收到。我们的客服代表将尽快与您联系!如需更快回复,请致电我们: +65 8129 8877
哎呀!提交表格时出错了。